Document is current
Any future updates will be listed below
-
Authors
Mirsaeidi, Mehdi https://orcid.org/0000-0001-5298-8442
Kaplan, Jeffrey
Affeldt, John
Berkovich, Regina
Askanase, Anca
-
Funding
Funding for this research was provided by:
Mallinckrodt Pharmaceuticals
- License Information
-
More Information
Article History
Received: 6 May 2025
Accepted: 26 August 2025
First Online: 15 September 2025
Declarations
:
: Mehdi Mirsaeidi does not have any conflicts of interest to disclose. Jeffrey Kaplan has served on and received compensation for speakers’ bureaus from AbbVie, Amgen, Biogen, Bristol Myers Squibb, EMD Serono, Lundbeck, Mallinckrodt, TG Therapeutics, and Vanda. Dr. Kaplan is currently affiliated with AdventHealth Medical Group Neurology, Roeland Park, Kansas. John Affeldt has served on and received compensation for speakers' bureaus, advisory boards, and/or consulting for Bausch & Lomb, Claris, Dompe, Kala, Mallinckrodt, ReGenTree, and Sun Pharmaceuticals. Regina Berkovich has received honoraria for speaking engagements, served on scientific advisory boards, and provided consulting for Alexion, Amgen, ANI Pharmaceuticals, Biogen, EMD Serono, Mallinckrodt Pharmaceuticals, Novartis, Sanofi, and TG Therapeutics. Anca Askanase has received consulting fees from AbbVie, Amgen, AstraZeneca, Aurinia, BMS, Celgene, Eli Lilly, Idorsia, Janssen, Genentech, GSK, Mallinckrodt, Pfizer, and UCB.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals that were used in any of the experiments performed by any of the authors.
